Showing 561 - 580 results of 6,070 for search '"death"', query time: 0.10s Refine Results
  1. 561
  2. 562
  3. 563
  4. 564
  5. 565
  6. 566

    Resilience in the time of crisis: A review of the maternal, perinatal and reproductive health effects of COVID-19 in South Africa by S Fawcus, S Gebhardt, R Niit, R Pattinson

    Published 2024-05-01
    Subjects: “…Covid 19, Maternal mortality, Perinatal Mortality, Causes of death, Service utilisation…”
    Get full text
    Article
  7. 567
  8. 568
  9. 569
  10. 570
  11. 571
  12. 572
  13. 573
  14. 574
  15. 575
  16. 576
  17. 577
  18. 578
  19. 579

    Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin by Jichao Sun, Dinglan Wu, Liuhai Zheng, Huifang Wang, Jihao Zhou, Guangwei Shi, Jingbo Ma, Yuke Jiang, Zhiyu Dong, Jiexuan Li, Yuan-Qiao He, Chengchao Xu, Zhijie Li, Jigang Wang

    Published 2024-07-01
    “…Here, we explore whether immunogenic cell death (ICD) marker ERp57 translocated from endoplasmic reticulum to cell surface after drug treatment could be used as a target for CAR-NK therapy.Methods To target ERp57, a VHH phage display library was used for screening ERp57-targeted nanobodies (Nbs). …”
    Get full text
    Article
  20. 580

    Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC by Christian Rolfo, MD, PhD, Laurent Greillier, MD, PhD, Remi Veillon, MD, PhD, Firas Badin, MD, MBA, Francois Ghiringhelli, MD, PhD, Nicolas Isambert, MD, PhD, Astrid Paulus, MD, PhD, Surendra Pal Chaudhary, MD, Yulia Vugmeyster, PhD, Masashi Sato, MSc, Sandrine Hiret, MD, PhD

    Published 2025-01-01
    “…This study evaluated the safety and efficacy of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC regardless of the programmed death-ligand 1 (PD-L1) expression status. Methods: In this open-label, phase 1b/2 study (NCT03840915), eligible patients were assigned to one of four cohorts. …”
    Get full text
    Article